Advertisement
Advertisement
U.S. markets open in 2 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Oxford Biomedica plc (OXB.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
503.65+1.65 (+0.33%)
As of 12:04PM BST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close502.00
Open509.99
Bid502.00 x 0
Ask504.00 x 0
Day's Range502.00 - 509.99
52 Week Range414.00 - 1,678.00
Volume10,290
Avg. Volume165,370
Market Cap483.918M
Beta (5Y Monthly)0.96
PE Ratio (TTM)22.89
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for OXB.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology

      Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform will be used to develop a producer cell line capab

    • GlobeNewswire

      Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy

      Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. The LSA grants the new partner a non-exclusive licence to uti

    • GlobeNewswire

      Oxford Biomedica Preliminary Results

      Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees

    Advertisement
    Advertisement